- Home
- ERII vs PHVS Comparison
ERII vs PHVS Comparison
Compare ERII & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERII
- PHVS
- Stock Information
- Founded
- ERII 1992
- PHVS 2015
- Country
- ERII United States
- PHVS Switzerland
- Employees
- ERII N/A
- PHVS N/A
- Industry
- ERII Industrial Machinery/Components
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- ERII Technology
- PHVS Health Care
- Exchange
- ERII Nasdaq
- PHVS Nasdaq
- Market Cap
- ERII 762.9M
- PHVS 1.3B
- IPO Year
- ERII 2008
- PHVS 2021
- Fundamental
- Price
- ERII $14.69
- PHVS $23.80
- Analyst Decision
- ERII Buy
- PHVS Strong Buy
- Analyst Count
- ERII 3
- PHVS 5
- Target Price
- ERII $18.67
- PHVS $35.60
- AVG Volume (30 Days)
- ERII 362.3K
- PHVS 123.8K
- Earning Date
- ERII 10-29-2025
- PHVS 11-12-2025
- Dividend Yield
- ERII N/A
- PHVS N/A
- EPS Growth
- ERII 25.10
- PHVS N/A
- EPS
- ERII 0.43
- PHVS N/A
- Revenue
- ERII $141,775,000.00
- PHVS N/A
- Revenue This Year
- ERII $6.16
- PHVS N/A
- Revenue Next Year
- ERII $13.06
- PHVS N/A
- P/E Ratio
- ERII $33.70
- PHVS N/A
- Revenue Growth
- ERII 6.19
- PHVS N/A
- 52 Week Low
- ERII $10.86
- PHVS $11.51
- 52 Week High
- ERII $20.27
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- ERII 59.71
- PHVS 57.29
- Support Level
- ERII $14.20
- PHVS $23.20
- Resistance Level
- ERII $14.65
- PHVS $24.02
- Average True Range (ATR)
- ERII 0.33
- PHVS 1.35
- MACD
- ERII -0.00
- PHVS 0.01
- Stochastic Oscillator
- ERII 95.70
- PHVS 70.49
About ERII Energy Recovery Inc.
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.